BridgeBio Pharma (BBIO)
(Delayed Data from NSDQ)
$24.95 USD
-0.03 (-0.12%)
Updated Apr 18, 2024 04:00 PM ET
After-Market: $24.98 +0.03 (0.12%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Income Statements
Fiscal Year end for BridgeBio Pharma, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 9 | 78 | 70 | 8 | 41 |
Cost Of Goods | 2 | 3 | 3 | 0 | 3 |
Gross Profit | 7 | 74 | 67 | 8 | 38 |
Selling & Adminstrative & Depr. & Amort Expenses | 614 | 586 | 643 | 483 | 304 |
Income After Depreciation & Amortization | -607 | -512 | -577 | -474 | -266 |
Non-Operating Income | 35 | 108 | 37 | 6 | -14 |
Interest Expense | 81 | 80 | 47 | 37 | 9 |
Pretax Income | -653 | -485 | -586 | -505 | -289 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | -10 | -3 | -24 | -57 | -28 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -653 | -485 | -586 | -505 | -289 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -643 | -481 | -563 | -449 | -261 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -601 | -505 | -571 | -471 | -266 |
Depreciation & Amortization (Cash Flow) | 6 | 7 | 6 | 3 | 0 |
Income After Depreciation & Amortization | -607 | -512 | -577 | -474 | -266 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 162.79 | 147.47 | 144.36 | 118.00 | 105.10 |
Diluted EPS Before Non-Recurring Items | -3.95 | -3.79 | -3.90 | -3.80 | -2.48 |
Diluted Net EPS (GAAP) | -3.95 | -3.26 | -3.90 | -3.80 | -2.48 |
Fiscal Year end for BridgeBio Pharma, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 1.75 | 4.09 | 1.64 | 1.83 |
Cost Of Goods | NA | 0.60 | 0.60 | 0.60 | 0.65 |
Gross Profit | NA | 1.15 | 3.49 | 1.04 | 1.18 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 178.57 | 161.19 | 147.14 | 127.34 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -177.42 | -157.70 | -146.10 | -126.16 |
Non-Operating Income | NA | 27.36 | -1.49 | 5.99 | 3.55 |
Interest Expense | NA | 20.27 | 20.31 | 20.59 | 20.12 |
Pretax Income | NA | -170.33 | -179.49 | -160.70 | -142.73 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | -2.18 | -2.49 | -2.80 | -2.58 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -170.33 | -179.49 | -160.70 | -142.73 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -168.15 | -177.00 | -157.90 | -140.16 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 174.46 | 163.31 | 160.54 | 152.65 |
Diluted EPS Before Non-Recurring Items | NA | -0.96 | -1.08 | -0.98 | -0.92 |
Diluted Net EPS (GAAP) | NA | -0.97 | -1.08 | -0.98 | -0.92 |